Abstract
Once the diagnosis of a neuroendocrine tumour has been made, characterisation is an essential step before therapy. It comes before the decision regarding treatment is made. This requires a multidisciplinary team of experts located in specialist centres that currently make up the RENATEN and TENPATH networks. It is directed by knowledge of the location of the primary tumour and anatomical pathological differentiation. The aim of this characterisation step is to highlight factors that may have an impact on the diagnosis and the prognosis or predict the response to treatment.
Résumé
Une fois le diagnostic de tumeur neuroendocrine (TNE) posé, la caractérisation est une étape essentielle de la prise en charge d’une TNE. Elle précède la décision thérapeutique. Celle-ci fait appel à une expertise multidisciplinaire au sein des centres experts actuellement regroupés au sein des réseaux RENATEN et TENpath. Elle est orientée par la connaissance de la localisation du primitif et la différenciation anatomopathologique. Cette étape de caractérisation a comme objectif: la mise en évidence de facteurs à impact diagnostique, pronostique ou prédictif de la réponse thérapeutique.
Similar content being viewed by others
Références
Baudin E, Bidart JM, Bachelot A, et al (2001) Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 12(Suppl 2): S79–S82
Durante C, Boukheris H, Dromain C, et al (2009) Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well differentiated endocrine carcinoma. Endocr Relat Cancer 16(2): 585–597
Jensen RT, Cadiot G, Brandi ML, et al (2012) ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95: 98–119
Kloppel G, Rindi G, Perren A, et al (2010) The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch 456: 595–597
Kwekkeboom DJ, de Herder WW, van Eijck CH, et al (2010) Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 40: 78–88
Madeira I, Terris B, Voss M, et al (1998) Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43: 422–427
Mitry E, Baudin E, Ducreux M, et al (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81: 1351–1355
Pavel M, Baudin E, Couvelard A, et al (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95: 157–176
Rindi GKD, Arnold R, Klöppel G, et al (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of the digestive system. IARC, Lyon, pp. 13–14
Scarpa A, Mantovani W, Capelli P, et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol: An Official Journal of the United States and Canadian Academy of Pathology, Inc 23: 824–833. (doi:10.1038/modpathol.2010.58)
Scoazec JY, Couvelard A; pour le réseau TENpath (réseau national d’expertise pour le diagnostic anatomopathologique des tumeurs neuroendocrines malignes de l’adulte, sporadiques et familiales) (2011) The new WHO classification of digestive neuroendocrine tumors. Ann Pathol 31: 88–92
Sobin LHGM, Wittekind C (2009) TNM Classification of malignant tumours. 7th Edition. Wiley, New York
Thakker RV, Newey PJ, Walls GV, et al (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97: 2990–3011
Thésaurus national de cancérologie digestive de la Société nationale française de gastroentérologie. Chapitre 11. Tumeurs endocrines digestives. Site http://www.tncd.org/. Mise à jour 2011
Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (2004) World Health Organization Classification of Tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. International Agency for Research on Cancer International Agency for Research on Cancer (IARC) Press, Lyon
Author information
Authors and Affiliations
Corresponding author
Additional information
pour le comité multidisciplinaire des tumeurs neuroendocrines
About this article
Cite this article
Baudin, E., Scoazec, J.Y., Caramella, C. et al. Caractérisation des tumeurs neuroendocrines digestives ou thoraciques. Oncologie 15, 505–509 (2013). https://doi.org/10.1007/s10269-013-2343-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-013-2343-1
Keywords
- Neuroendocrine tumours
- Prognosis factors
- Diagnostic impact
- Characterisation
- Response to treatment
- Multidisciplinary expertise
- RENATEN and TENPATH networks